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Ten-eleven translocation 1–3 (Tet1–3) proteins have re-
cently been discovered in mammalian cells to be members
of a family of DNA hydroxylases that possess enzymatic
activity toward the methyl mark on the 5-position of
cytosine (5-methylcytosine [5mC]), a well-characterized
epigenetic modification that has essential roles in regu-
lating gene expression and maintaining cellular identity.
Tet proteins can convert 5mC into 5-hydroxymethylcyto-
sine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcyto-
sine (5caC) through three consecutive oxidation reactions.
These modified bases may represent new epigenetic states
in genomic DNA or intermediates in the process of DNA
demethylation. Emerging biochemical, genetic, and func-
tional evidence suggests that Tet proteins are crucial for
diverse biological processes, including zygotic epigenetic
reprogramming, pluripotent stem cell differentiation, he-
matopoiesis, and development of leukemia. Insights into
how Tet proteins contribute to dynamic changes in DNA
methylation and gene expression will greatly enhance our
understanding of epigenetic regulation of normal devel-
opment and human diseases.
The development of a multicellular organism follows a
series of spatiotemporally defined biological processes.
During development, stem and progenitor cells differen-
tiate into functionally diverse cell types with unique gene
expression profiles, which are regulated, at least in part,
by cell type-specific covalent modifications of DNA and
histones (Jaenisch and Bird 2003). These epigenetic mod-
ifications are largely responsible for cells with identical
genomes stably displaying distinct cellular phenotypes.
DNA cytosine methylation is one of the best-charac-
terized epigenetic modifications and plays important
roles in a variety of cellular processes, including retro-
transposon silencing, genomic imprinting, X-chromosome
inactivation, regulation of gene expression, and mainte-
nance of epigenetic memory (Bird 2002). In mammalian
genomes, methylation of cytosine predominantly occurs
at CpG dinucleotides; however, pervasive DNA meth-
ylation in non-CG contexts (CpH, where H = A, C, or T)
has been reported in mouse and human embryonic stem
(ES) cells (;25% of all methylcytosines in human ES
cells) (Ramsahoye et al. 2000; Lister et al. 2009). New
DNA methylation patterns are initially established by de
novo DNA methyltransferases: Dnmt3a and Dnmt3b
(Okano et al. 1998; Okano et al. 1999). The pattern of
DNA methylation is then faithfully maintained during
DNA replication by the maintenance methyltransferase
Dnmt1, which is recruited to replication foci via its physical
interaction with the ubiquitin-like plant homeodomain
and RING finger domain 1 (Uhrf1) that strongly binds
to hemimethylated DNA (Bestor et al. 1988; Hermann
et al. 2004; Bostick et al. 2007; Sharif et al. 2007). Deletion
of Dnmt1 or Dnmt3b results in embryonic lethality,
whereas homozygous Dnmt3a knockout mice die ;4 wk
after birth (Li et al. 1992; Okano et al. 1999), suggesting
that DNA methyltransferases are essential for normal
mammalian development. Mutations in the DNA meth-
ylation machinery have long been linked to inherited
human diseases. For example, mutations in the human
DNMT3B gene cause immunodeficiency centromeric
instability facial anomalies (ICF) syndrome (Okano et al.
1999; Xu et al. 1999). Aberrant DNA methylation is also
linked to imprinting disorders, such as Prader-Willi/
Angelman syndrome (PWS/AS), as well as human can-
cers (Robertson 2005). Together, these studies have
firmly established the importance of precise regulation
of DNA methylation patterns in normal mammalian
development.
Compared with readily reversible modifications of his-
tone proteins, DNA methylation was generally considered
to be a relatively stable epigenetic modification. However,
bisulphite sequencing analysis as well as immunofluo-
rescence staining using 5-methylcytosine (5mC)-specific
antibodies indicated that global erasure of DNA meth-
ylation can take place in specific embryonic stages, such
as zygotes (Mayer et al. 2000; Oswald et al. 2000) and
developing primordial germ cells (PGCs) (Hajkova et al.
2002; Sasaki and Matsui 2008). In addition, recent
genome-wide analysis of the DNA methylation pattern
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in pluripotent and differentiated cells at single-nucleo-
tide resolution indicated that DNA methylation can be
dynamically regulated during cellular differentiation
(Meissner et al. 2008; Lister et al. 2009). These obser-
vations suggest the existence of mammalian enzymatic
activities capable of erasing or modifying pre-existing
DNA methylation patterns. However, the identity of
such enzymes has been enigmatic and is the subject of
intense research (Ooi and Bestor 2008; Wu and Zhang
2010).
Human ten-eleven translocation 1 (TET1) and mouse
Tet proteins have recently been identified to have the ca-
pacity to convert 5mC to 5hmC (5-hydroxymethylcyto-
sine) (Tahiliani et al. 2009; Ito et al. 2010), raising the
possibility that 5mC distribution can be dynamically reg-
ulated by the Tet family of DNA hydroxylases. Further-
more, the presence of novel 5mC oxidation derivatives in
genomic DNA may provide an additional layer of epige-
netic information. In this review, we discuss the current
knowledge about the mechanism and functions of Tet
protein-mediated oxidation of 5mC. We begin by describ-
ing the recent progress toward elucidating the enzy-
matic activity of these DNA hydroxylases and detection
methods for 5mC oxidation derivatives. We then discuss
the role of Tet proteins in DNA demethylation as well
as their roles in normal development and initiation of
leukemia. We conclude by highlighting the remaining
important questions in this emerging field.
Enzymatic activity of Tet proteins
The founding member of the Tet family of DNA hydrox-
ylases, the TET1 gene, was initially identified in acute
myeloid leukemia (AML) as a fusion partner of the histone
H3 Lys 4 (H3K4) methyltransferase MLL (mixed-lineage
leukemia) (Ono et al. 2002; Lorsbach et al. 2003). Rao and
colleagues (Tahiliani et al. 2009) have recently shown that
human TET1 protein possesses enzymatic activity capable
of hydroxylating 5mC to generate 5hmC. They were
interested in Tet proteins because of their sequence sim-
ilarity to the Trypanosome base J (b-D-glucosyl-hydroxy-
methyl-uracil)-binding proteins JBP1 and JBP2 (Iyer et al.
2009), which are capable of hydrolyzing the methyl group
of thymine (Borst and Sabatini 2008). Our group extended
their finding by demonstrating that all members of the
mouse Tet protein family (Tet1–3) have 5mC hydroxylase
activities (Ito et al. 2010). Tet proteins contain several
conserved domains (Fig. 1; Tahiliani et al. 2009), including
a CXXC domain that has high affinity for clustered
unmethylated CpG dinucleotides and a catalytic domain
that is typical of Fe(II)- and 2-oxoglutarate (2OG)-depen-
dent dioxygenases. In agreement with the known reaction
Figure 1. Domain architecture of mouse Tet proteins. Schematic diagrams of predicted functional domains in the mouse Tet proteins
(Tet1–3). Three conserved domains—including CXXC zinc finger, the cysteine-rich region (Cys-rich), and the double-stranded b-helix
(DSBH) fold of the 2OG-Fe(II) dioxygenase domain—are indicated. Numbers represent the amino acid numbers. Note that Tet2 does not
contain a predicted CXXC domain. Multiple sequence alignment of the catalytic motif of the JBP/Tet family of dioxygenases.
Sequences used in the alignment include the Trypanosoma brucei JBP1 (Q9U6M3) and JBP2 (Q57X81); human TET1 (Q8NFU7), TET2
(Q6N021), and TET3 (O43151); and mouse Tet1 (GU079948), Tet2 (GU079949), and Tet3 (Q8BG87). Numbers represent the amino acid
numbers. Alignment was performed using MultAlin (http://bioinfo.genotoul.fr/multalin). The color code is defined by the MultAlin
program. Predicted Fe(II)- and 2OG-binding sites are highlighted.
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mechanism of dioxygenases (Loenarz and Schofield 2011),
mutation of putative iron-binding sites of Tet proteins
abolishes their enzymatic activities (Tahiliani et al. 2009;
Ito et al. 2010). In addition, 2-hydroxyglutarate (2-HG),
a competitive inhibitor of 2OG-dependent dioxygenases,
suppresses the catalytic activity of Tet proteins (W Xu
et al. 2011). Interestingly, both fully methylated and hemi-
methylated DNA in a CG or non-CG context can serve as
substrates for TET1 (Tahiliani et al. 2009; Ficz et al. 2011;
Pastor et al. 2011).
Thymine 7-hydroxylase (THase), also a member of
2OG-dependent dioxygenases, acts as a key enzyme in
the thymidine salvage pathway in fungi (e.g., Neurospora
crassa) and catalyzes three sequential oxidation reactions
to convert thymine (T) to iso-orotate, which is subse-
quently processed by a decarboxylase to produce uracil
(U) (Smiley et al. 2005; Neidigh et al. 2009). Based on the
similar chemistry between 5mC oxidation and the T-to-U
conversion, we previously hypothesized that, in theory,
Tet proteins should be able to further oxidize 5hmC to
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)
(Wu and Zhang 2010). However, previous studies failed to
detect these predicted enzymatic products, likely due to
limitations of the assay employed (Tahiliani et al. 2009;
Ito et al. 2010). Indeed, with modified experimental con-
ditions, our group and others have recently shown that Tet
proteins are capable of further oxidizing 5hmC to 5fC and
5caC (He et al. 2011; Ito et al. 2011). Importantly, 5fC and
5caC can be detected in genomic DNA of mouse ES cells
(He et al. 2011; Ito et al. 2011; Pfaffeneder et al. 2011).
Consistent with its in vitro activity, overexpression of Tet2
protein in human HEK293 cells, where endogenous Tet
protein levels are low, can produce readily detectable levels
of 5fC and 5caC in an enzymatic activity-dependent
manner (Ito et al. 2011). Conversely, levels of 5fC and
5caC in mouse ES cells are significantly reduced in re-
sponse to Tet1 knockdown (Ito et al. 2011). These results
suggest that Tet protein-mediated oxidation of 5mC may
initiate enzymatic cascades that dynamically modify the
pre-existing mammalian DNA methylation pattern.
Quantifying and mapping 5mC oxidation derivatives
Cytosine methylation has long been recognized as ‘‘the
fifth base’’ in mammalian DNA. Early work noted that
the hydroxylated form of 5mC, 5hmC, is present in
T-even bacteriophage DNA and is often further modified
by glycosylation to protect the phage genome from being
degraded by restriction enzymes present in infected hosts
(Wyatt and Cohen 1952; Vrielink et al. 1994). The recent
discoveries of the sixth base, 5hmC, by the Heintz and
Rao groups (Kriaucionis and Heintz 2009; Tahiliani et al.
2009) and of additional 5mC oxidation derivatives (5fC
and 5caC) by our and other groups (He et al. 2011; Ito et al.
2011; Pfaffeneder et al. 2011) in the mammalian genome
have fueled a strong interest in quantifying global levels
as well as mapping genomic distribution of these modi-
fied cytosine bases in various cell types and tissues.
However, commonly used approaches for DNA meth-
ylation studies, including bisulphite genomic sequencing
and methylation-sensitive restriction enzyme digestion,
cannot discriminate 5hmC from 5mC (Huang et al. 2010;
Jin et al. 2010). There is also evidence suggesting that
5caC is interpreted as C after bisulphite treatment and
PCR amplification (He et al. 2011). Thus, bisulphite se-
quencing, the standard technique used in analyzing DNA
methylation patterns, cannot distinguish 5mC from its
oxidation derivatives. To circumvent such technical chal-
lenges, several strategies exploiting specific biochemical
or biophysical properties of modified cytosine bases have
been developed. These strategies include (1) thin-layer
chromatography (TLC) analysis of modified nucleotides
(Ito et al. 2010; Kriaucionis and Heintz 2009; Tahiliani et al.
2009), (2) mass spectrometry (MS) analysis (Ito et al. 2011;
Munzel et al. 2010; Globisch et al. 2011), (3) modification-
specific antibodies (Ficz et al. 2011; Williams et al. 2011;
Wu et al. 2011a), (4) selective chemical labeling of modified
cytosine (Szwagierczak et al. 2010; Song et al. 2011; Pastor
et al. 2011), and (5) real-time sequencing (Fig. 2; Flusberg
et al. 2010).
TLC assay
TLC is a classic method that separates different nucleo-
tides or different modified forms of the same nucleotide
based on their differential migration rates on TLC plates.
Using the methylation-insensitive restriction enzyme
MspI and a TLC assay, Tahiliani et al. (2009) estimated
that the 5hmC level in mouse ES cells is ;0.03% of total
nucleotides. Upon leukemia inhibitory factor (LIF) with-
drawal, 5hmC levels are reduced to ;40% in differenti-
ated mouse ES cells, consistent with a concomitant de-
crease in Tet1 and Tet2 mRNA levels (Koh et al. 2011).
Using a two-dimensional (2D) TLC method and nearest-
neighbor analysis, Kriaucionis and Heintz (2009) reported
that 5hmC level is ;0.6% and 0.2% of total nucleotides
in Purkinje and granule neurons, respectively. However,
under standard TLC buffer conditions, 5hmC and 5fC
have almost identical migration patterns, and 5caC fails
to migrate (Ito et al. 2011). To overcome this technical
issue, we developed a modified 2D TLC assay in conjunc-
tion with the use of TaqI, a restriction enzyme that is
insensitive to all cytosine modifications, allowing for
clear separation of 5mC and its oxidation products (Fig.
2A; Ito et al. 2011).
Liquid chromatography (LC) and MS
To better quantify the global levels of 5mC oxidation
derivatives, several groups have developed MS-based
methods. Using stable isotope-labeled reference com-
pounds and LC-MS, Gobisch et al. (2011) found that
5mC levels are relatively similar in all tested mouse
tissues (;4.3% of all cytosine or 43 3 103 5mC in every
106 C). However, 5hmC levels varied significantly be-
tween different tissues, with the highest levels of 5hmC
found in various brain tissues (3 3 103 to 7 3 103 5hmC in
every 106 C); medium levels in kidney, nasal epithelia,
bladder, heart, muscle, and lung (1.5 3 103 to 1.7 3 103
5hmC in every 106 C); and low levels in pituitary gland,
liver, spleen, and testes (0.3 3 103 to 0.6 3 103 5hmC in
Wu and Zhang
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every 106 C) (Munzel et al. 2010; Globisch et al. 2011).
Using a similar approach, the same group recently
discovered that 5fC is also present in mouse ES cells
and estimated that 5%–10% of 5hmC in mouse ES cell
DNA is further oxidized to 5fC (0.2 3 103 5fC in every 106
C vs. 3.9 3 103 5hmC in every 106 C) (Pfaffeneder et al.
2011). Upon differentiation by LIF withdrawal or in
Dnmt3a/3b-deficient mouse ES cells, 5fC level is signif-
icantly reduced, reinforcing the notion that 5fC is gener-
ated from pre-existing 5mC/5hmC by Tet proteins. Using
a quantitative LC-MS assay, our group recently charac-
terized the enzymatic kinetics of the Tet-catalyzed itera-
tive oxidation reaction and quantified the endogenous
levels of 5hmC, 5fC, and 5caC (Fig. 2B; Table 1). This
analysis indicated that the genomic content of these
modified bases in mouse ES cells is ;1.3 3 103 5hmC,
20 5fC, and three 5caC in every 106 C, respectively (Ito
et al. 2011). While 5hmC and 5fC are also present in
various mouse tissues, 5caC can only be reliably detected
in mouse ES cells (Table 1; Ito et al. 2011).
Modification-specific antibodies
DNA methylation patterns can be determined by using
antibodies against 5mC or methyl-CpG-binding domains
(MBDs). Similarly, antibodies specific for 5hmC, which
are available from both commercial (e.g., Diagenode and
Active Motif) and academic (Williams et al. 2011) sour-
ces, have been used for genome-wide mapping of 5hmC
distribution by high-throughput sequencing or whole-
Figure 2. Detection methods of 5mC oxidation derivatives. (A) Schematic diagrams of in vitro biochemical assays followed by 2D
TLC. The spots corresponding to 5mC and its oxidation products are indicated in a representative 2D TLC plate. (B) Flow chart of the
procedures used for quantifying 5mC oxidation derivatives in mouse genomic DNA. Representative data of high-performance LC
(HPLC) and LC-MS/MS assays are shown. (C) Schematic representations of how antibodies specific to 5mC oxidation products can be
used in immunoprecipitation or immunostaining assays. (D) Schematic representation of the 5hmC glucosylation reaction catalyzed by
b-glucosyltransferase (b-GT) of T-even bacteriophages.
Tet and DNA demethylation
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genome tiling microarrays (Fig. 2C; Ficz et al. 2011; Jin
et al. 2011; Stroud et al. 2011; Szulwach et al. 2011; Wu
et al. 2011a; Y Xu et al. 2011). Antibodies specific for 5mC
and 5hmC are also extensively used in immunostaining
assays to examine cellular levels of these epigenetic marks
in various biological systems, such as zygotes, developing
embryos, and adult brains (Ficz et al. 2011; Iqbal et al. 2011;
Ruzov et al. 2011; Wossidlo et al. 2011). In addition, Pastor
et al. (2011) took advantage of the fact that bisulphite
treatment converts 5hmC into cytosine 5-methylene-
sulphonate (CMS) and developed specific antisera against
CMS. As specific antibodies against 5fC or 5caC become
available, they can be used in a similar way to determine
the cellular levels as well as the genome-wide location of
these newly identified 5mC oxidation derivatives.
Chemical labeling of 5mC oxidation derivatives
While the antibody-based detection methods for 5mC
oxidation derivatives are convenient to use and advanta-
geous in immunostaining assays, it has been reported that
the immunoprecipitation efficiency of 5hmC antibodies
are partially dependent on the density of CpG sites (Pastor
et al. 2011). Therefore, sparsely distributed 5hmC marks
in genomic DNA may not be readily detected using the
5hmC antibody. To further improve the sensitivity of
5hmC detection methods, several groups developed selec-
tive chemical labeling approaches for 5hmC by exploiting
the naturally occurring glucosylation process of 5hmC by
b-glucosyltransferase (b-GT) in T-even bacteriophages (Fig.
2D; Szwagierczak et al. 2010; Pastor et al. 2011; Song et al.
2011). Such strategy allows for the addition of a glucose
moiety to the hydroxyl group of 5hmC using b-GT to
yield b-glucosyl-5-hmC. For instance, Song et al. (2011)
used purified b-GT to transfer a custom-synthesized
UDP-glucose analog (UDP-6-N3-glucose) onto 5hmC.
With an azide group present in the chemically modified
glucose, a biotin group or other tags can be attached to
5hmC using click chemistry for various applications
(Song et al. 2011). A similar approach, termed GLIB
(glucosylation, periodate oxidation, and biotinylation),
was developed by Rao and colleagues (Pastor et al. 2011).
In vitro binding assays suggest that these chemical
labeling methods may possess enhanced sensitivity for
detecting 5hmC marks sparsely distributed in genomic
DNA (Pastor et al. 2011). Importantly, chemical labeling
strategy can also be used to add biotin tags to 5fC and 5caC
(Ito et al. 2011; Pfaffeneder et al. 2011), providing a poten-
tial method to compare the relative abundances of differ-
ent 5mC oxidation derivatives.
Single-molecule real-time (SMRT) sequencing
While modification-specific antibody or chemical label-
ing methods can detect the presence of 5mC oxidation
derivatives within genomic DNA fragments (200- to 500-
base-pair [bp] resolution), neither of the above approaches
provides the modification status of cytosine at single-
base-pair resolution. Thus, it is challenging to precisely
map 5mC and its derivatives when these modified bases
are within the same DNA fragments. A recent study has
reported promising results on the development of SMRT
sequencing, which uses the capacity of DNA polymerase
to incorporate C, 5mC, and 5hmC with different kinetics
(Flusberg et al. 2010). While the robustness of this tech-
nology as well as whether this technology can discrimi-
nate 5hmC from 5fC and 5caC remain to be seen, real-time
sequencing technologies provide a potential tool to map
the various cytosine derivatives at base-pair resolution
without the need for bisulphite treatment.
Tet-mediated 5mC oxidation and DNA demethylation
Although the biological significance of Tet-mediated
oxidation of 5mC is largely unclear, the relative abundance
of 5mC oxidation derivatives such as 5hmC in genomic
DNA suggests that these modified cytosine bases may play
important roles in modulating 5mC-dependent gene regu-
latory and biological functions. Indeed, MBD-containing
proteins such as methyl-CpG-binding protein 2 (MeCP2)
Table 1. Quantification of 5mC and its oxidation derivatives in genomic DNA of HEK293 cells, and mouse ES cells and tissues
Number per million C
Cell type/tissue 5mC 5hmC 5fC 5caC
HEK293 26,000 90 4.4 n.d.
HEK293, Tet2 CD wild type 13,000 7540 1629 517
HEK293, Tet2 CD mut 26,000 140 1.7 n.d.
Mouse ES cells (E14), Con knockdown 29,500 1250 19 3.4
Mouse ES cells (E14), Tet1 knockdown 30,500 580 7.8 n.d.
Mouse brain cortex 31,000 6690 16 n.d.
Mouse kidney 27,000 2110 3 n.d.
Mouse lung 27,500 1630 3.7 n.d.
Mouse heart 27,000 1440 4.6 n.d.
Mouse pancreas 25,000 935 5.9 n.d.
Mouse liver 27,500 1435 6.7 n.d.
Mouse spleen 29,000 575 12 n.d.
Mouse thymus 30,500 235 4.3 n.d.
Levels of modified cytosine bases in genomic DNA are shown as the average of two biological replicates measured by high-performance
LC (HPLC)-LC-MS/MS (Ito et al. 2011). (CD) Catalytic domain; (mut) catalytic activity-deficient mutant; (E14) embryonic day 14; (n.d.)
cannot be reliably determined.
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do not recognize 5hmC (Valinluck et al. 2004; Jin et al.
2010), thereby providing a potential means to reverse the
gene silencing effect mediated by promoter DNA methyl-
ation-dependent recruitment of MBD proteins and their
associated corepressor protein complexes (Nan et al. 1998;
Feng and Zhang 2001). In addition, 5mC oxidation deriv-
atives such as 5hmC may regulate local chromatin struc-
ture by directly recruiting specific DNA-binding proteins.
Interestingly, in vitro DNA-binding and molecular simu-
lation analyses suggest that the SET- and RING-associated
(SRA) domain of Uhrf1 protein, a key factor in methylation
maintenance, binds to not only hemimethylated but also
hemi- or fully hydroxymethylated CpG sites (Frauer et al.
2011), suggesting a role for Uhrf1 in mediating 5hmC-
dependent functions.
Emerging evidence suggests that Tet protein-mediated
5mC oxidation may also contribute to dynamic changes
in global or locus-specific 5mC levels by facilitating both
passive and active DNA demethylation. Because 5hmC
is not recognized by Dnmt1 during DNA replication
(Valinluck and Sowers 2007), conversion of 5mC to 5hmC
will prohibit the maintenance of existing DNA methyl-
ation patterns and lead to passive DNA demethylation in
proliferating cells. This replication-dependent dilution
mechanism of 5hmC may be important for genome-wide
erasure of 5mC in the paternal genome in zygotes and
preimplantation embryos (see below). Furthermore, 5mC
oxidation derivatives may represent intermediate prod-
ucts in the process of replication-independent active
DNA demethylation (enzymatic conversion of 5mC to
C). Although it is well established that plants (e.g.,
Arabidopsis thaliana) use the Demeter (DME)/repressor
of silencing 1 (ROS1) family of 5mC glycosylases and the
base excision repair (BER) pathway to achieve active
DNA demethylation (Zhu 2009), a mammalian ortholog
of the DME/ROS1 family of glycosylases has yet to be
identified. How active DNA demethylation takes place in
mammals has been controversial (Ooi and Bestor 2008;
Wu and Zhang 2010). The discovery of 5mC oxidation
derivatives in mammalian cells immediately raises the
possibility that Tet proteins may play a role in the process
of active DNA demethylation (Tahiliani et al. 2009; Wu
and Zhang 2010). Here we discuss existing biochemical,
genetic, and functional evidences for three proposed
enzymatic pathways of active DNA demethylation initi-
ated by Tet proteins (Fig. 3).
Iterative 5mC oxidation followed by DNA
glycosylase/BER
As discussed above, Tet proteins can generate 5hmC, 5fC,
and 5caC through iterative oxidation of 5mC (He et al.
2011; Ito et al. 2011). These 5mC oxidation derivatives
can potentially serve as substrates for mammalian DNA
glycosylases or deaminases (see below). Indeed, recent
studies have demonstrated that thymine DNA glycosylase
(TDG) can efficiently excise 5fC or 5caC in the context of
CpG sites (He et al. 2011; Maiti and Drohat 2011). Thus,
subsequent repair of the resulting abasic site would
regenerate unmethylated cytosine. Interestingly, TDG
removes 5fC from the G:5fC substrate at a rate even faster
(;40%) than processing the G:T mismatch (Maiti and
Drohat 2011), probably due to the weakened N-glycosidic
bond between the nucleobase and the sugar (Bennett et al.
2006). In contrast, TDG has essentially no activity for
5hmC (Maiti and Drohat 2011). The robust excision
activity of TDG toward 5fC and 5caC may be one
explanation as to why 5fC and 5caC are present at very
low levels in the genome compared with 5hmC (Ito et al.
2011; Pfaffeneder et al. 2011). In agreement with the
proposal that TDG promotes active demethylation, de-
letion of TDG in mice leads to embryonic lethality and
aberrantly elevated DNA methylation levels at a cohort of
gene promoters (Cortazar et al. 2011; Cortellino et al.
2011). In contrast, other DNA glycosylases, such as single-
strand-selective monofunctional U DNA glycosylase 1
(SMUG1) and MBD protein 4 (MBD4), have no significant
activity for excision of 5fC and 5caC from DNA (He et al.
2011; Maiti and Drohat 2011), suggesting that TDG might
be the only mammalian DNA glycosylase to have robust
excision activity for 5fC and 5caC. Thus, these findings
lead to a multistep active DNA demethylation model
linking Tet1-mediated iterative oxidation of 5mC and
the BER pathway initiated by the TDG DNA glycosylase
(Fig. 3). However, it is important to note that although
depletion of TDG in mouse ES cells resulted in an
Figure 3. Proposed models of Tet-initiated
DNA demethylation pathways. DNA
methylation (5mC) is established and
maintained by DNA methyltransferases
(Dnmt). In mammals, 5mC can be hydrox-
ylated by the Tet family of dioxygenases
to generate 5hmC. 5hmC is recognized
poorly by Dnmt1 and can lead to replica-
tion-dependent passive demethylation.
5hmC can be further oxidized by Tet pro-
teins to produce 5fC and 5caC. Alterna-
tively, 5hmC may be further deaminated
to become 5hmU by AID/APOBECC de-
aminases. 5hmU, 5fC, and 5caC can be
excised from DNA by glycosylases such
as TDG. A putative decarboxylase may directly convert 5caC to C. Cytosine and its derivatives are highlighted in red. DNA
glycosylase TDG-catalyzed reactions are indicated by blue arrows.
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increase in the 5caC level (He et al. 2011), the amount of
estimated 5caC under TDG-depleted conditions is still
below the level of 5fC under normal conditions (He et al.
2011; Ito et al. 2011). Given the high efficiency of full-
length Tet2 in converting 5mC to 5caC (He et al. 2011), it
is anticipated that 5caC would accumulate at a much
higher level under TDG depletion conditions if TDG is
the only enzyme capable of processing 5caC. Therefore, it
is possible that additional enzymes that possess 5caC
processing activity exist in mammalian cells.
5hmC deamination followed by DNA glycosylase/BER
Another potential active DNA demethylation pathway
that can be initiated by Tet proteins involves deamina-
tion of 5hmC followed by DNA repair. In this scenario,
5hmC may first be deaminated by the AID (activation-
induced deaminase)/APOBEC (apolipoprotein B mRNA-
editing enzyme complex) family of cytidine deaminases
to produce 5-hydroxymethyluracil (5hmU), followed by
5hmU:G mismatch repair through the action of DNA
glycosylases and the BER pathway (Fig. 3). This hypoth-
esis is supported by recent studies demonstrating that
DNA glycosylases such as TDG and SMUG1 exhibit
robust excision activity against 5hmU:G in dsDNA
(Cortellino et al. 2011), whereas they have no or very
low 5hmC glycosylase activity in an in vitro biochemical
assay (Cortellino et al. 2011; He et al. 2011). Furthermore,
studies in human HEK293 cells demonstrated that TDG
can directly interact with AID (Cortellino et al. 2011),
suggesting that the deamination and DNA glycosylase
activity may be coupled.
However, one open question that remains to be ad-
dressed is to what extent the AID/APOBEC family of
cytidine deaminases is used to deaminate 5hmC to gener-
ate 5hmU in vitro and in vivo (Fig. 3). Whereas AID and
APOBEC1 are shown to possess the capacity to deaminate
5mC to T in the context of ssDNA in vitro (Morgan et al.
2004), no direct biochemical evidence suggests that these
deaminases exhibit robust activity for 5hmC. In addition,
mass spectrometric analysis indicates that 5hmU, the
predicted intermediate of this pathway, does not accumu-
late to a detectable level in mammalian cells (Globisch
et al. 2011; Pfaffeneder et al. 2011). This indicates that
either the deamination reaction does not occur extensively
in vivo or 5hmU is extremely short-lived. In agreement
with this, although AID may contribute to active PGC
demethylation in vivo (Popp et al. 2010), it is probably
responsible for only a small portion of this large-scale
demethylation process, as substantial demethylation still
occurs in the absence of AID. Nevertheless, 5hmC de-
amination followed by the BER pathway does seem to be a
potential mechanism underlying loci-specific active de-
methylation. For example, a recent study has suggested
that Tet1 and AID may cooperate in demethylating a
methylated DNA duplex (Guo et al. 2011). In this study,
cotransfection of plasmid DNA encoding various AID/
APOBEC deaminases with a linearized 5mC- or 5hmC-
containing reporter into HEK293 cells resulted in locus-
specific demethylation of 5hmC- but not 5mC-containing
dsDNA (Guo et al. 2011). Interestingly, Guo et al. (2011)
also observed that 5hmC in a non-CpG context is more
frequently demethylated than those in CpG dinucleotides
(;9% for 5hmCpHs vs. ;2% for 5hmCpGs), and 5hmC
in the nontranscribed strand seems to be preferentially
demethylated.
Iterative 5mC oxidation followed by decarboxylation
Both mechanisms described above involve glycosylases
and the DNA repair pathway. Such mechanisms are un-
likely to be used in large-scale DNA demethylation pro-
cesses observed in PGCs and zygotes, as genome-wide
repair of mismatches in such a limited time window will
put tremendous pressure on genome stability. Therefore,
we previously proposed a simple mechanism involving
Tet-mediated iterative oxidation followed by decarboxyl-
ation (Wu and Zhang 2010). Given that only two enzymes
are required to convert 5mC to C in this hypothetical
mechanism (Fig. 3), it obviates the need for a DNA strand
break that is required for DNA repair-based mechanisms,
thereby relieving the pressure of genome instability
associated with BER. Despite the simplicity of this pro-
posed demethylation pathway and the precedent of a
decarboxylase in thymidine salvage reactions, the exis-
tence of the putative decarboxylase capable of removing
carboxyl group from 5caC to regenerate unmodified
cytosine remains to be revealed.
Genomic distribution of Tet1 and 5hmC, and their role
in transcriptional regulation
A prevailing view of the role of DNA methylation in gene
regulation is that DNA methylation primarily functions
in long-term gene silencing. Indeed, DNA methylation
at the gene promoter can either block the binding of
transcriptional factors or facilitate the recruitment of
MBD-associated corepressor complexes (Bird 2002). How-
ever, recent genome-wide methylome analyses in plurip-
otent stem cells and differentiated cells indicate that not
only is promoter methylation dynamic during cellular
differentiation, but actively transcribed genes tend to be
associated with high levels of gene body DNA methyla-
tion (Meissner et al. 2008; Suzuki and Bird 2008; Lister
et al. 2009). A recent genome-wide mapping and functional
study of the de novo DNA methyltransferase Dnmt3a also
provide evidence supporting the view that DNA methyl-
ation may play a role in both gene repression and activa-
tion (Wu et al. 2010). These genome-wide DNA methyla-
tion studies have therefore revealed a more complex,
context-dependent role for DNA methylation in transcrip-
tional regulation.
To better understand the gene regulatory function of
Tet proteins and 5mC oxidation, we and others recently
mapped distribution of Tet1 and 5hmC across the genome
of mouse and human ES cells (Ficz et al. 2011; Pastor et al.
2011; Stroud et al. 2011; Szulwach et al. 2011; Williams
et al. 2011; Wu et al. 2011a,b; Y Xu et al. 2011). Compar-
ative analysis of data sets from different laboratories in-
dicates that different Tet1 antibodies and 5hmC mapping
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methods generated similar results (Wu and Zhang 2011).
Using pluripotent ES cells as a model system, these genome-
wide analyses uncovered several key features of genomic
occupancy of Tet1 and 5hmC as well as their potential
functions in transcriptional regulation (Fig. 4).
First, Tet1 exhibits a strong preference for genomic re-
gions with densely clustered CpG dinucleotides, termed as
CpG islands (CGIs) (Williams et al. 2011; Wu et al. 2011b;
Y Xu et al. 2011), which are generally free of DNA
methylation and frequently overlapped with transcrip-
tional start sites (Deaton and Bird 2011). This is possibly
due to the presence of a CpG-binding CXXC zinc finger
domain in Tet1 (Fig. 1; Iyer et al. 2009; Zhang et al. 2010).
Interestingly, the CXXC domain has also been found
in other epigenetic regulators such as Cfp1 (CXXC finger
protein 1) and the H3K36me2 (dimethylated H3K36) his-
tone demethylase Kdm2a that are enriched at unmeth-
ylated CGIs (Blackledge et al. 2010; Thomson et al. 2010),
raising the possibility that these CXXC domain-containing
proteins may cooperate in contributing to the establish-
ment of a transcriptionally permissive chromatin state at
CGIs (Deaton and Bird 2011). An attractive scenario is
that, at a majority of CGIs, Cfp1 promotes trimethylation
of Lys 4 on histone H3 (H3K4me3) via recruitment of the
H3K4me3 methyltransferase Setd1 (Thomson et al. 2010),
Kdm2a reduces the level of H3K36me2 (Blackledge et al.
2010), and Tet1 maintains a DNA hypomethylated state
by actively removing any sporadic de novo DNA methyl-
ation. In support of this model, Tet1-bound CGIs are DNA
hypomethylated, and Tet1 deficiency results in an increase
in 5mC levels at many Tet1-enriched regions (Wu et al.
2011b; Y Xu et al. 2011).
Second, both Tet1 and 5hmC are highly enriched at
gene promoters that are associated with bivalent domains
(Pastor et al. 2011; Williams et al. 2011; Wu et al. 2011a,b;
Y Xu et al. 2011), which are marked with the transcrip-
tional permissive mark H3K4me3 as well as the Poly-
comb repression complex 2 (PRC2) deposited repressive
mark H3K27me3. Bivalent gene promoters are generally
associated with poised developmentally regulated genes,
particularly lineage-specific transcription factors, sug-
gesting a role for Tet1 and 5hmC in promoting a repressive
but ‘‘poised’’ state at these gene promoters. In agreement
with this model, depletion of Tet1 in mouse ES cells
results in impaired recruitment of Ezh2 (a core subunit of
PRC2) to bivalent gene promoters (Wu et al. 2011b),
indicating that Tet1 and 5hmC may functionally contrib-
ute to the maintenance of the undifferentiated state of
mouse ES cells by facilitating PRC2-mediated repression of
lineage-specific genes. Interestingly, although 5mC at pro-
moters is also linked to gene repression, 5mC is not
enriched at bivalent gene promoters (Fouse et al. 2008).
Thus, 5hmC and 5mC may have different regulatory func-
tions at gene promoters.
Third, Tet1 and 5hmC seem to play dual functions in
transcription regulation. Chromatin immunoprecipitation
(ChIP) combined with sequencing (ChIP-seq) analyses
from multiple laboratories have revealed that Tet1 binds
to promoters of highly transcribed as well as PRC2-re-
pressed genes (Wu and Zhang 2011). Genome-wide expres-
sion profiling of control and Tet1-depleted mouse ES cells
also indicates that Tet1 may have both repressive and ac-
tivating functions on its direct target genes (Williams et al.
2011; Wu et al. 2011b; Y Xu et al. 2011). A significant
fraction of genes aberrantly up-regulated in Tet1-depleted
mouse ES cells are Tet1/PRC2-cobound and transcription-
ally repressed lineage-specific genes (Wu et al. 2011b),
whereas a cohort of actively transcribed Tet1 target genes,
including several pluripotency-related transcription fac-
tors (e.g., Nanog, Tcl1, and Esrrb), are found to be down-
regulated in the absence of Tet1 (Ficz et al. 2011; Wu et al.
2011b). In addition, 5hmC has been shown to be enriched
in both the gene body of highly transcribed genes (partic-
ularly at exons) and the promoters of PRC2-repressed
genes (Ficz et al. 2011; Pastor et al. 2011; Williams et al.
2011; Wu et al. 2011a; Y Xu et al. 2011), further supporting
Figure 4. Relationship of Tet1/5hmC and transcrip-
tion in mouse ES cells. Schematic representation of
the relative enrichment of Tet1 and major histone
modifications (H3K4me3 and H3K27me3), as well as
the distribution of 5mC/5hmC at four major classes
of genes: (1) Highly transcribed genes with a CpG-
rich promoter are associated with high levels of Tet1
and H3K4me3 at their promoters, as well as high
levels of 5mC/5hmC within their gene bodies (par-
ticularly at 39 intragenic regions). (2) Actively tran-
scribed genes with CpG-poor promoters (e.g., a
subset of pluripotency factors such as Nanog and
Tcl1) are associated with medium/low levels of Tet1
and 5hmC at their promoters as well as within their
gene bodies. (3) Polycomb-repressed yet ‘‘poised’’
genes (e.g., lineage-specific transcription factors)
are enriched with high levels of Tet1, 5hmC,
H3K4me3, and H3K27me3 at their extended pro-
moters. (4) Silent genes with a CpG-poor promoter (e.g., tissue-specific genes) are generally associated with sparsely distributed 5mC
and 5hmC at their proximal promoter, but are devoid of high levels of Tet1 and PRC2. (TSS) Transcriptional start site; (TES)
transcriptional end site.
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a potential role for 5hmC in both transcriptional repres-
sion and activation (Robertson et al. 2011). Interestingly,
Williams et al. (2011) also showed that Tet1 associates
with the Sin3A corepressor complex to repress a subset
of Tet1 targets, and the transcriptional repression func-
tion of Tet1 appears to be independent of its enzymatic
activity in mouse ES cells. Further studies are needed to
determine whether the enzymatic activity-independent
transcriptional function of Tet1 is specific to pluripotent
stem cells or is a general mechanism that also operates
in other cell types.
Finally, 5hmC, but not 5mC, is enriched at many
intergenic cis-regulatory elements, such as active en-
hancers and insulator-binding sites (Ficz et al. 2011;
Pastor et al. 2011; Williams et al. 2011; Wu et al. 2011a).
Recent genome-wide mapping studies of 5hmC in hu-
man ES cells also confirmed that 5hmC is enriched
at binding sites of many transcriptional factors related to
pluripotency (Stroud et al. 2011; Szulwach et al. 2011),
indicating a conserved role for Tet1 and 5hmC in con-
trolling gene expression through regulation of enhancer
functions.
Together, genome-wide studies in undifferentiated ES
cells and during ES cell differentiation have provided
detailed information regarding the distribution of Tet1
and 5hmC and supported the notion that Tet1-mediated
gene regulation plays an important role in orchestrating
the balance between the pluripotent state and initiation
of cellular differentiation. Genome-wide analysis of other
5mC oxidation derivatives is likely to provide additional
insights into the role of Tet proteins in gene regulation
and active DNA demethylation.
Biological functions of Tet proteins in development
and diseases
Although all Tet family members (Tet1–3) possess 5mC
oxidation activity, their expression levels in various cell
types and tissues are very different (Ito et al. 2010). For
example, Tet1 and Tet2 are highly expressed in mouse ES
cells, but Tet3 is more enriched in oocytes and one-cell
zygotes. The distinct expression pattern of Tet1–3 suggests
that these proteins may play nonoverlapping biological
functions in a developmentally regulated and tissue-spe-
cific manner.
Role of Tet3-mediated 5mC oxidation in zygotic
DNA demethylation
While DNA methylation patterns are relatively stable in
somatic cells, rapid erasure of global DNA methylation
patterns has been observed in developing PGCs as well as
zygotes (Sasaki and Matsui 2008; S Feng et al. 2010; Wu
and Zhang 2010). In one-cell zygotes, the 5mC mark in
the paternal pronucleus quickly disappears before the
first cell division (depicted in orange in the top panel of
Fig. 5; Mayer et al. 2000; Oswald et al. 2000), whereas the
maternal genome is proposed to be protected from
zygotic demethylation by DNA-binding proteins, such
as Stella/Dppa3 (Nakamura et al. 2007). Using specific
antibodies against 5hmC or 5mC, recent studies have
shown that the paternal and maternal genomes of mouse
zygotes at late pronuclear (PN4–5) stages are predomi-
nantly marked by 5hmC and 5mC, respectively, and that
appearance of 5hmC (around PN3 stage) coincides with
the loss of 5mC marks in the paternal genome (summa-
Figure 5. Dynamic changes of 5mC and 5hmC levels in the paternal and maternal genomes during preimplantation development.
Tet3 is highly expressed in the oocyte and one-cell zygote. Immediately after fertilization, Tet3 may potentially relocate from the
cytoplasm to the paternal nucleus to convert 5mC to 5hmC. Subsequently, paternal and maternal genomes undergo replication-
dependent dilution of 5hmC and 5mC, respectively. It is important to note that replication-independent active DNA demethylation
may occur at specific loci, but the exact mechanism is currently unclear. New DNA methylation patterns in the ICM are re-established
by de novo DNA methyltransferases Dnmt3a and Dnmt3b. (TE) Trophectoderm.
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rized in the bottom panel of Fig. 5; Iqbal et al. 2011;
Wossidlo et al. 2011). The asymmetric marking of 5hmC
in the paternal pronucleus is also observed in bovine and
rabbit zygotes (Wossidlo et al. 2011), suggesting a con-
served role for oxidation of 5mC in the erasure of paternal
5mC immediately after fertilization. Gene expression
analysis indicated that Tet3, but not Tet1 and Tet2, is
expressed at high levels in oocytes and zygotes, but
rapidly decreases at two-cell and later stages (Iqbal et al.
2011; Wossidlo et al. 2011). In agreement with the notion
that Tet3 is responsible for 5mC oxidation in the paternal
pronucleus, either conditional deletion of Tet3 from the
female germ cells or siRNA-mediated down-regulation of
zygotic Tet3 impedes the conversion of 5mC to 5hmC in
the paternal genome (Gu et al. 2011; Wossidlo et al. 2011).
Furthermore, Tet3 protein appears to be specifically en-
riched in the paternal pronucleus at the zygotic stage
(Gu et al. 2011). Subsequent bisulphite sequencing anal-
ysis suggests that zygotic Tet3 may be required for active
DNA demethylation at specific loci in the paternal ge-
nome, including Line1 transposons and gene regulatory
regions of pluripotency factors (Oct4 and Nanog), which
are hypermethylated in sperm. However, loss of Tet3
does not affect the methylation status of several imprint-
ing loci (Gu et al. 2011). Interestingly, Tet3 is dispensable
for germ cell maturation, fertilization, and preimplanta-
tion development, but deletion of Tet3 from either PGCs
(TNAP-Cre) or growing oocytes (Zp3-Cre) resulted in in-
creased frequency of developmental failure of embryos,
possibly due to delayed/attenuated activation of the pa-
ternal allele of genes important for embryogenesis (Gu
et al. 2011). In addition, somatic cell nuclear transfer
(SCNT) using Tet3-deficient oocytes, but not control oo-
cytes, resulted in failure in 5mC oxidation of somatic
genomes, impaired demethylation at the somatic Oct4
promoter, and activation of an Oct4-EGFP transgene (Gu
et al. 2011). Together, these results suggest that Tet3 acts
as a critical factor for zygotic epigenetic reprogramming
by initiating the global conversion of 5mC to 5hmC and
possibly other oxidation forms.
Interestingly, asymmetric marking of 5hmC in sperm-
derived chromosomes persists into two-cell stage embryos
(Iqbal et al. 2011), suggesting that 5hmC is not rapidly
removed on a genome-wide scale. Thus, it is important to
determine the fate of paternal 5hmC during preimplanta-
tion development. As discussed above (Fig. 3), 5hmC/5fC/
5caC can be actively processed through enzymatic re-
actions or be passively diluted through DNA replication.
In a recent study, careful analysis of high-resolution mi-
totic chromosome spreads that are positive for 5hmC
staining at the one-, two-, four-, and eight-cell stages
indicates that 5hmC marks on the paternal chromosomes
are gradually lost from the one- to eight-cell stage, and this
process appears to be mediated by replication-dependent
dilution, as, on average, half of the chromosomes retain
the 5hmC mark after each round of cell division (Inoue and
Zhang 2011). The above results support the model in
which global erasure of paternal 5mC is first initiated by
Tet3-mediated conversion of 5mC to 5hmC in the male
pronucleus, followed by replication-dependent passive loss
of 5hmC during preimplantation development. Similarly,
a replication-dependent passive demethylation mecha-
nism has been proposed to be responsible for global loss
of 5mC marks on the maternal chromosomes (Rougier
et al. 1998). While these findings cannot exclude the
possibility that 5mC oxidation derivatives may also serve
as intermediates for replication-independent active DNA
demethylation pathways (Fig. 3), whether and how specific
loci in paternal and maternal genomes undergo actual
DNA demethylation (conversion of 5mC/5hmC to C, not
just to 5fC or 5caC) in zygotes and preimplantation
embryos awaits further investigation, as bisulphite se-
quencing analysis cannot discriminate 5caC from unmeth-
ylated cytosine (He et al. 2011). Of note, a recent study
identified the elongator complex as a potential regulator
of zygotic paternal genome demethylation (Okada et al.
2010; Wu and Zhang 2010). It will be of interest to
determine whether elongator and Tet3 proteins cooperate
to mediate the erasure of paternal 5mC. Given that
developing PGCs also undergo global erasure of 5mC
(Hajkova et al. 2002; Sasaki and Matsui 2008), it will be
interesting to determine whether Tet-mediated 5mC oxi-
dation is also involved in PGC demethylation.
Role of Tet1 in regulating pluripotency and lineage
differentiation of mouse ES cells
Concomitant with the rapid reduction of Tet3 expression
at the two-cell stage, the expression of Tet1 is rapidly up-
regulated at later preimplantation stages (Iqbal et al. 2011;
Wossidlo et al. 2011). As the zygote develops into the
blastocyst, Tet1 and Tet2 are expressed at high levels in
the inner cell mass (ICM). Consistently, Tet1 and Tet2,
but not Tet3, are expressed in mouse ES cells. Upon in
vitro differentiation of mouse ES cells, Tet1 and Tet2
expression is rapidly decreased, whereas Tet3 expression
is up-regulated (Tahiliani et al. 2009; Ito et al. 2010; Koh
et al. 2011). Given that both Tet1 and Tet2 are direct
downstream targets of a cohort of pluripotency factors
(Koh et al. 2011) and that Tet1 binds to gene promoters of
some key ES cell transcription factors (Wu and Zhang
2011), Tet proteins are likely to be part of the pluripo-
tency regulatory circuit.
shRNA-mediated Tet1 knockdown in mouse ES cells
suggests that Tet1 deficiency leads to a decrease in total
5hmC levels (;50%) and increased DNA methylation at
the Nanog-proximal promoter, which is accompanied by
a decrease in Nanog expression and impaired prolifera-
tion of ES cells (Ito et al. 2010). Subsequent genome-wide
location analyses in mouse ES cells have confirmed that
Tet1 and 5hmC are enriched at promoter regions of
several pluripotency factors, including Nanog, Tcl1, and
Esrrb (Wu and Zhang 2011). RNA-seq analysis of Tet1 and
Tet2 double knockdown mouse ES cells also showed that
several genes related to pluripotency are down-regulated
in the absence of Tet proteins (Ficz et al. 2011). However,
other studies using different sets of shRNAs to down-
regulate Tet1 and Tet2 suggest that Tet1/2 deficiency does
not affect the expression of pluripotency factors and mouse
ES cell proliferation (Koh et al. 2011; Williams et al. 2011).
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These discrepancies between in vitro experiments are
possibly due to differences in mouse ES cell background,
culturing conditions, and/or off-target effects of shRNAs
(Williams et al. 2011; Wu and Zhang 2011). Further
analysis of lineage-specific gene expression and teratomas
indicate that Tet1 deficiency leads to increased sponta-
neous differentiation toward trophoectoderm and meso-
endoderm lineages (Ito et al. 2010; Ficz et al. 2011; Koh
et al. 2011). The above results, together with recent
findings on the dual functions of Tet1 in both Polycomb
repression of developmental genes and transcriptional
activation of pluripotency genes, suggest that Tet1 is
potentially required for orchestrating the balance between
pluripotency maintenance and lineage commitment.
To further study the function of Tet1 in ES cell main-
tenance and in vivo development, Jaenisch and colleagues
(Dawlaty et al. 2011) recently generated Tet1-null mouse
ES cells and mice. In Tet1-null mouse ES cells, a decrease
in 5hmC levels (;35%) is observed and 221 genes are
found to be significantly dysregulated. However, Tet1-
null ES cells maintain a normal morphology, express
proper levels of key pluripotency factors, and support
embryonic development in a tetraploid complementation
assay (Dawlaty et al. 2011). While Jaenisch and colleagues
(Dawlaty et al. 2011) also observed altered expression of
lineage-specific marks (Brachyury and Pax6) in differen-
tiating mutant ES cells and skewed differentiation toward
trophectoderm in Tet1-null teratomas, Tet1 mutant ES
cells fail to exhibit similar phenotypic defects in vivo.
These results suggest that in vitro differentiation defects
exhibited in mutant ES cells and teratoma assays are less
pronounced in the context of embryonic development in
vivo. Further analysis of Tet1-null mice indicate that
mutant mice are viable, but 75% of the homozygous
mutant pups display a smaller body size at birth, suggest-
ing loss of Tet1 leads to a developmental delay. Moreover,
both male and female germ cells are generated in homo-
zygous mutant embryos, but the number of progenies
derived from the intercross of Tet1-null males and females
are significantly reduced, indicating that either a subset of
Tet1-null mice are embryonic lethal or germ cell develop-
ment is impaired in homozygous Tet1-null mice (Dawlaty
et al. 2011). Given that Tet1 is highly expressed in devel-
oping PGCs (Hajkova et al. 2010), further investigations
are required to elucidate the role of Tet1 in epigenetic re-
programming of PGCs and gametogenesis.
Role of Tet proteins in brain development
and activity-dependent DNA demethylation
Brain-specific deletion of DNA methyltransferases re-
sults in premature death, neural developmental defects,
and impaired neuronal functions (Fan et al. 2001, 2005;
Nguyen et al. 2007; J Feng et al. 2010; LaPlant et al. 2010;
Wu et al. 2010). Loss-of-function mutations of the
X-chromosome-linked gene encoding MECP2 causes Rett
syndrome, an autism spectrum disorder predominantly
found in girls (Amir et al. 1999). These findings suggest
that precise control of DNA methylation patterns is
required for proper brain development. Among various
mouse cell types and tissues, neurons in the CNS appear
to contain the highest levels of 5hmC, almost 10 times
higher than that of mouse ES cells, suggesting that Tet
proteins may play a critical role in brain development and
maturation.
Using a chemical labeling strategy to determine the
total amount of 5hmC in the mouse cerebellum at dif-
ferent stages of development, Song et al. (2011) report a
gradual increase from postnatal day 7 (P7; 0.1% of all
nucleotides) to adult stage (0.4%). They also determined
the genome-wide distribution of 5hmC in P7 and adult
cerebellum (Song et al. 2011). This analysis identified
5425 genes acquiring 5hmC during aging. Among them,
genes related to age-dependent neurodegenerative disor-
ders, angiogenesis, and hypoxia response are enriched.
Previous studies show that active DNA demethylation
at specific gene promoters (e.g., Bdnf and Fgf1) may be
required for activity-dependent adult neurogenesis (Ma
et al. 2009; Wu and Sun 2009). A more recent study
indicates that Tet1 may contribute to this process by
initiating 5mC hydroxylation followed by AID/APOBEC-
mediated deamination and BER (Guo et al. 2011). These
results raise the possibility that 5hmC may play a critical
role in postnatal neural development, age-related neuro-
degeneration, and transcriptional regulation of activity-
dependent neural plasticity.
Role of Tet2 in hematopoiesis and leukemia
Aberrant DNA methylation pattern is one of the hall-
marks of cancer cells (Esteller 2008; Gal-Yam et al. 2008).
In general, cancer cells display global hypomethylation
and promoter hypermethylation of tumor suppressor
genes. Consistently, accumulating evidence suggests that
somatic mutations in DNA methyltransferases and 5mC-
modifying enzymes, such as TET proteins, are associated
with oncogenic transformation. For instance, mutations
in the de novo DNA methyltransferase DNMT3A were
recently found in a significant fraction of patients with
AML (Shah and Licht 2011; Yan et al. 2011).
The first evidence implicating TET proteins in tumor-
igenesis was the identification of TET1 as a rare fusion
partner of MLL in patients with AML (Ono et al. 2002;
Lorsbach et al. 2003). The chromosome 4q24 harbors the
human TET2 gene and displays recurrent microdeletions
and copy-neutral loss of heterozygosity in patients with
myeloid malignancies (Viguie et al. 2005). In 2009, two
studies identified somatic TET2 mutations in patients
with myeloproliferative neoplasms (MPNs) and myelodys-
plastic syndromes (MDSs) (Delhommeau et al. 2009;
Langemeijer et al. 2009). Subsequent investigations of
larger cohorts of leukemia patients suggest that TET2
mutations are frequently observed in a diverse spectrum
of myeloid malignancies, including MDS (19%–26%),
MPN (12%–37%), chronic myelomonocytic leukemia
(CMML; 20%–50%), de novo AML (7%–23%), and second-
ary AML (sAML) (Abdel-Wahab et al. 2009; Delhommeau
et al. 2009; Langemeijer et al. 2009; Tefferi et al.
2009a,b; Abdel-Wahab 2011; Pronier et al. 2011). Most
recently, recurrent TET2 mutations were also identified
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in B- and T-cell lymphoma (Quivoron et al. 2011). For
detailed discussion of clinical aspects of TET2 muta-
tions in hematopoietic malignancies, please refer to a
recent review by Aifantis and colleagues (Cimmino et al.
2011).
To better understand the mechanism by which somatic
TET2 mutations contribute to leukemia, several studies
examined the effect of disease-associated mutations on
TET2 catalytic activity and global epigenetic profiles. Ko
et al. (2010) demonstrated that TET2 mutations found in
patients with myeloid malignancies impair its enzymatic
activity. Consistently, genomic DNA derived from pa-
tient bone marrows with TET2 mutations contains sig-
nificantly lower levels of 5hmC compared with that from
healthy controls (Ko et al. 2010). Interestingly, samples
from patients with low 5hmC levels also display a hypo-
methylated state relative to controls at the majority
of differentially methylated CpG sites (Ko et al. 2010).
However, a recent integrative genetic and methylation
analysis of a large, homogeneous cohort of AML patients
showed that TET2 mutations are predominantly associ-
ated with a DNA hypermethylation state (Figueroa et al.
2010). The discrepancies between these two studies are
probably due to differences in disease subtypes (diverse
myeloid malignancies vs. de novo AML only) and meth-
ylation profiling platforms (Illumina Infinium methyla-
tion assay vs. HpaII tiny fragment enrichment by ligation-
mediated PCR [HELP] assay). Given that both methyla-
tion assays used in previous studies only assess a subset of
CpG sites at gene promoter regions, unbiased genome-
wide mapping of 5mC and 5hmC distribution is required
to better understand the extent of alterations in DNA
methylation associated with TET2 mutations.
Interestingly, recent mutational analyses of AML pa-
tients have shown that TET2 and the isocitrate dehydro-
genase gene IDH1/2 mutations are mutually exclusive
(Figueroa et al. 2010). IDH1/2 are NADP-dependent en-
zymes that catalyze the conversion of isocitrate to 2OG.
Recurrent somatic mutations of IDH1/2 are frequently
found in glioma and AML patients (Parsons et al. 2008;
Mardis et al. 2009; Yan et al. 2009; Gross et al. 2010;
Marcucci et al. 2010; Ward et al. 2010). Subsequent studies
showed that mutant IDH enzymes predominantly acquire
a neomorphic function to produce 2-HG, an oncometabo-
lite that impairs catalytic activity of many Fe(II)- and 2OG-
dependent dioxygenases, including the JmjC family of
histone demethylases (Klose et al. 2006) and the Tet family
of DNA hydroxylases. 2-HG inhibits the enzymatic ac-
tivity of these enzymes by competing with their cosub-
strate, 2OG (Dang et al. 2009; Gross et al. 2010; Ward
et al. 2010; W Xu et al. 2011). These studies suggest that
IDH1/2 mutations may alter DNA methylation patterns
by inhibiting TET2 enzymatic activity. Indeed, methyla-
tion profiling of samples from AML patients with IDH1/2
mutations has demonstrated that patient samples ex-
hibited elevated DNA methylation at differentially meth-
ylated regions when compared with control samples
(Figueroa et al. 2010). Collectively, these results suggest
that loss-of-function TET2 mutations and neomorphic
IDH1/2 mutations in hematopoietic malignancies may
share a common disease mechanism and pathoetiology
that lead to alteration in 5hmC and 5mC patterns (Fig. 6).
Thus, therapies modulating catalytic activity of TET
proteins might be beneficial for the treatment of patients
with TET2 mutations.
Frequent mutations of TET2 in leukemia patients
suggest that TET2 may function as a physiological regu-
lator of hematopoiesis. To elucidate the functions of
TET2 in hematopoietic differentiation and homeostasis,
several groups have used various genetic approaches to
investigate the effect of Tet2 deficiency on normal he-
matopoiesis. The approaches include shRNA-based Tet2
knockdown and targeted deletion of Tet2 in mice (Figueroa
et al. 2010; Ko et al. 2010, 2011; Li et al. 2011; Moran-
Crusio et al. 2011; Quivoron et al. 2011). Despite different
phenotypic results between reports using in vitro knock-
down of Tet2 (Figueroa et al. 2010; Ko et al. 2010; Moran-
Crusio et al. 2011), all Tet2-null mouse models generated
highly similar phenotypes. Although all three Tet family
proteins are expressed in hematopoietic systems, deletion
of Tet2 alone is sufficient to cause significant loss of 5hmC
in genomic DNA. Importantly, Tet2 deletion led to gradual
enlargement of the stem/progenitor cell pool in a cell-
autonomous manner, as shown by increased expression of
stem cell marker genes (e.g., c-Kit) as well as markedly
elevated self-renewal capacity. Intriguingly, all Tet2-null
mouse models progressively develop myeloid neoplasms,
despite minor differences in disease onset time and pro-
gression kinetics. Consistent with the high frequency
of TET2 mutations in human CMML, Tet2-null mouse
models exhibited predominantly CMML-like disease. Fur-
thermore, functional analysis showed that Tet2 haploin-
Figure 6. Leukemic mutations of TET2 or IDH1/2
lead to altered 5mC and 5hmC patterns at tumor
suppressor gene promoters. TET2 mutations that
impair the conversion of 5mC to 5hmC may cause
increased DNA methylation at tumor suppressor
gene promoters. Neomorphic mutations of IDH
proteins also inhibit TET2 enzymatic activity by
producing oncometabolite 2-HG (denoted as a trian-
gle), which competes with 2OG (denoted as a circle)
for TET2. Aberrant methylation of gene promoters
may result in decreased transcription of tumor sup-
pressors. Notably, TET2 and IDH mutations are
mutually exclusive in AML patients.
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sufficiency is sufficient to confer increased self-renewal to
stem/progenitor cells and promote myeloproliferation in
vivo (Moran-Crusio et al. 2011; Quivoron et al. 2011),
suggesting clinically relevant gene dosage effects. Thus,
Tet2 plays a critical role in regulating normal hematopoi-
etic differentiation and homeostasis, and deletion of Tet2
is sufficient to initiate myeloid transformation.
Concluding remarks and perspectives
Since the discovery of Tet family of proteins in 2009,
remarkable progress has been made in characterizing
their enzymatic activities, developing methods for de-
tection of newly identified enzymatic products, and un-
derstanding the role of Tet-mediated 5mC oxidation in
DNA demethylation and transcriptional regulation. Ge-
netic deletion analysis in mice has further revealed that
Tet proteins play essential roles in zygotic epigenetic
reprogramming, stem cell differentiation, hematopoiesis,
and the development of myeloid malignancies.
Despite the significant progress, several key questions
about the mechanisms and functions of Tet proteins are
yet to be answered. First, current data suggest that Tet-
mediated oxidation of 5mC is involved in both passive
and active DNA demethylation. While 5mC hydroxylation
can clearly lead to replication-dependent global erasure
of 5mC in the paternal pronucleus, multiple enzymatic
pathways (e.g., 5mC oxidation/DNA glycosylase, AID/
APOBEC deaminase-mediated 5hmC deamination/DNA
glycosylase, and 5mC oxidation/putative decarboxylase)
might be used to complete the process of active DNA
demethylation initiated by Tet proteins. Thus, additional
investigations are needed to define the physiological con-
text, mechanistic details, and relative importance of each
of the potential pathways in the process of active DNA
demethylation. Second, genome-wide analysis of Tet1 and
5hmC distribution in mouse ES cells suggests that Tet
proteins may have dual functions in transcriptional regu-
lation. It is currently unclear how deposition of 5hmC and/
or other oxidation derivatives at different regulatory re-
gions (e.g., promoters, gene body, and enhancers) can con-
tribute to distinct transcriptional states. Third, given that
Tet3 may potentially translocate from the oocyte cyto-
plasm to the paternal pronucleus at the zygotic stage and
that 5hmC accumulates to significant levels at specific
genomic regions, it is likely that associating factors and/or
post-translational modifications are required for regulating
localization and enzymatic activity of Tet proteins. Fourth,
the fact that 5hmC accumulates to a significant level in
certain organs and tissues suggests that it may function as
a bona fide epigenetic mark for the recruitment of specific
‘‘reader’’ proteins. Thus, identification of proteins that can
specifically recognize 5hmC or other 5mC oxidation de-
rivatives may reveal the function of these new epigenetic
marks. Fifth, the observation that Tet proteins are capable
of sequentially oxidizing 5mC/5hmC/5fC suggests that
they can use different substrates. To elucidate substrate
recognition and catalysis mechanisms, high-resolution
cocrystallization structures of Tet proteins and their sub-
strates are needed.
In addition to biochemical and genomic studies, a sig-
nificant advance in understanding the biological func-
tions of Tet proteins is the generation of mouse models
for all three Tet genes. Given their unique expression
patterns, it is anticipated that further functional studies of
single and combinatorial knockout mice will uncover
distinct as well as overlapping functions of different Tet
proteins in the normal development of various somatic
tissues and germ cells. Finally, given that the human TET2
gene is frequently mutated in a variety of hematopoietic
neoplasms, integrative genome-wide analysis aimed at
delineating direct targets of Tet2 during normal hemato-
poiesis will provide mechanistic insights into the role
of Tet2 in myeloid malignancies. In summary, the discov-
ery of the Tet family of DNA hydroxylases and related
oxidation derivatives highlights the dynamic nature of
epigenetic modification of DNA and suggests that DNA
methylation and demethylation may play a critical role in
diverse biological processes. If the exciting progress in the
past 2 years is any indication, answers to the questions
raised above will not be too far away.
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